Ispire's Stock Trading Volume Decreases 51% on November 5th

Business by 2FIRSTS.ai
Dec.06.2023
Ispire's Stock Trading Volume Decreases 51% on November 5th
Ispire (ISPR) stock trades strong with a volume of 35,318 shares, down 51% from the previous day.

According to a report by Rivertonroll on December 5th, the trading volume of Ispire (Ispire Technology Inc., Nasdaq stock code: ISPR) was strong on November 5th. During the trading period, a total of 35,318 shares were traded, a decrease of 51% compared to the previous trading day's volume of 72,489 shares. The stock ended at a trading price of $9.92, up from the previous closing price of $9.85.

 

The stock's 50-day simple moving average is $9.79, while its 200-day simple moving average is $9.28.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Energy Marketers of America Backs White House Crackdown on Illicit Vape Shops, Urges Cleanup of ‘Gray Area’ Market
Energy Marketers of America Backs White House Crackdown on Illicit Vape Shops, Urges Cleanup of ‘Gray Area’ Market
The Energy Marketers of America (EMA) has publicly endorsed the White House’s enforcement campaign against illicit vape shops, saying it will help address the regulatory “gray area” that has emerged since 2020 due to delayed product approvals. EMA noted that a large volume of unauthorized imported disposable e-cigarettes worth about $86.5 million has been seized and called for stronger, more localized enforcement efforts to ease the burden on compliant convenience retailers.
Dec.04 by 2FIRSTS.ai
South Korea Implements Law Requiring Full Disclosure of Tobacco Harmful Substances
South Korea Implements Law Requiring Full Disclosure of Tobacco Harmful Substances
South Korea has enacted the Tobacco Harm Management Act, effective November 1, 2025, requiring tobacco manufacturers and importers to test and report harmful substances in their products every two years. Results for all tobacco types—including combustible cigarettes, heated tobacco, and e-cigarettes—will be publicly available from mid-2026.
Nov.04 by 2FIRSTS.ai
Imperial Brands Urges Retailers to Engage in Government Consultation on Tobacco and Vapes Bill
Imperial Brands Urges Retailers to Engage in Government Consultation on Tobacco and Vapes Bill
Imperial Brands is calling on UK retailers to take part in the Government’s consultation on the Tobacco and Vapes Bill, which will shape a new licensing framework for nicotine product sales across England, Wales and Northern Ireland. The Department of Health and Social Care’s call for evidence closes on 3 December 2025. Imperial Brands stresses this is a key chance for retailers to influence policy, support fair competition, and help curb illicit sales.
Nov.04
BAT Launches glo Hilo in Italy, Plans to Add 16 Local Production Lines to Support Mass Manufacturing and Export
BAT Launches glo Hilo in Italy, Plans to Add 16 Local Production Lines to Support Mass Manufacturing and Export
BAT Italy has launched the new heated tobacco device glo Hilo in Milan, with sticks 100% made in Italy. The company plans to add 16 new production lines at its Trieste hub to support manufacturing and exports, as part of a €500 million investment in Italy’s next-generation tobacco sector.
Oct.24 by 2FIRSTS.ai
Kenya Court of Appeal Halts BBC Defamation Case Linked to BAT Bribery Documentary
Kenya Court of Appeal Halts BBC Defamation Case Linked to BAT Bribery Documentary
Kenya’s Court of Appeal has paused the defamation proceedings filed by National Assembly Speaker Moses Wetang’ula against the BBC. The case centers on a 2015 BBC documentary, Panorama: The Secret Bribes of Big Tobacco, which alleged that Wetang’ula received unlawful benefits from British American Tobacco (BAT) during his tenure as a senator.
Dec.02 by 2FIRSTS.ai
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.
Oct.20 by 2FIRSTS.ai